Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -68.77
- Piotroski Score 1.00
- Grade Neutral
- Symbol (OGEN)
- Company Oragenics, Inc.
- Price $0.27
- Changes Percentage (-5.56%)
- Change -$0.02
- Day Low $0.27
- Day High $0.29
- Year High $7.74
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/14/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$8.47
- Trailing P/E Ratio -0.2
- Forward P/E Ratio -0.2
- P/E Growth -0.2
- Net Income $-20,655,737
Income Statement
Quarterly
Annual
Latest News of OGEN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
A list of top genomics stocks includes Biogen Inc. (NASDAQ:BIIB). Genomics sector is rapidly growing due to technological advancements reducing costs and time to map genomes. Investors like Cathie Woo...
By Yahoo! Finance | 1 day ago -
Uniper Picks Electric Hydrogen's Tech For 200-MW Green Hydrogen Project
Uniper has chosen Electric Hydrogen as its exclusive partner to design a 200-MW electrolyzer plant for large-scale electrolysis in Northern Germany. The Green Wilhelmshaven project aims to produce gre...
By Yahoo! Finance | 3 days ago -
Needham downgrades Biogen on slow growth of Alzheimer's drug
Needham downgraded Biogen Inc due to slower growth of Alzheimer's drug, Leqembi, and lack of major catalysts in the next year. The brokerage reduced revenue estimates for Leqembi and mentioned potenti...
By Yahoo! Finance | 3 days ago
